LX9211

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals has successfully transitioned from a discovery-focused research organization to a commercial-stage biopharma company following the FDA approval of INPEFA® for heart failure in May 2023. Its core strategy is built upon a systematic, genetics-driven discovery platform that validates novel drug targets in vivo, aiming to de-risk development and deliver first-in-class therapeutics. The company's mission is to address significant unmet medical needs, with current efforts centered on commercializing INPEFA and advancing late-stage candidates like LX9211 for neuropathic pain. Lexicon's future hinges on executing its commercial launch, expanding INPEFA's label, and translating its unique platform into additional high-value clinical assets.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals has successfully transitioned from a discovery-focused research organization to a commercial-stage biopharma company following the FDA approval of INPEFA® for heart failure in May 2023. Its core strategy is built upon a systematic, genetics-driven discovery platform that validates novel drug targets in vivo, aiming to de-risk development and deliver first-in-class therapeutics. The company's mission is to address significant unmet medical needs, with current efforts centered on commercializing INPEFA and advancing late-stage candidates like LX9211 for neuropathic pain. Lexicon's future hinges on executing its commercial launch, expanding INPEFA's label, and translating its unique platform into additional high-value clinical assets.

Therapeutic Areas